00:00So we are focusing on revolutionizing early cancer screening. That's our
00:08mission statement. We're very proud of what we're doing. We have a very unique
00:12way of tackling this issue. So as you can see here, our test is very simple. All
00:16you have to do is just breathe into the mask for three minutes, put it back in
00:21the canister and send it back to the lab. That's all that is required from the
00:25user. Where the magic happens is in the lab. So in the lab we combine two
00:29powerful things. First, the amazing sense of smell of canines and then we combine
00:35it with a technology platform called Lucid. So basically it has the
00:40engineering to process the mask, produce gas, introduce it to the dogs and also
00:46we have an AI component. So we have sensors in the lab to monitor the dogs
00:51both physiological and behavioral signals and we have a lot of cameras and
00:57sensors. This whole plethora of information is being fed into machine
01:01learning and that in turn help us determine which sample is negative and
01:05positive at a very high degree of accuracy. Some people might say, well this
01:10sounds great but this is dealing with something that's so important like
01:13cancer. What do you say to those people and how do you make sure that you do have
01:17that super accuracy that's so important in this space? I'm a molecular biologist by
01:22training. When Sportitory first approached me three years ago I was
01:26skeptic. But then as it happened they just published their interim results from the
01:31clinical study and I could not argue with the evidence. So we completed that
01:35study, 1400 patients, 94% sensitivity across four cancers. You cannot argue with these
01:43results. We now actually launched the clinical study in the US just two months ago
01:47and we're going to expand into other cancers as well. So the proof is in the
01:51pudding. We see the results and hopefully we can go to market soon enough.
01:56We completed the study in Israel. It was a multi-site study so in multiple
01:59hospitals. It was double blind so we didn't know the identity of the patients
02:04or the results. So the way it works you deposit your predictions with a third
02:09party so and then there's a big reveal. Obviously we lost a lot of sleep during that
02:14month. But now what we want to do is make sure that we match the cohort of our
02:20target market which is the US market. Although the Israeli market is diverse in
02:25terms of the patients, there's different diversity to every country so we want to
02:29make sure it works under this setting as well. How does that work with the dogs?
02:34Because I've seen before them doing other things like detecting low blood sugar
02:38and things like that. Is it really like they have that sensitive of a smell that
02:42they can just figure it out? That's incredible. Yeah it's a great question. So
02:45the dog sensitivity it's part per trillion. That's a lot. It's very
02:50sensitive. It's three orders of magnitude better than any artificial instrument.
02:54That's very, that's why we're using them as sensors. And I set aside the fact
02:59that they're great colleagues and fun to work with. So that's the reason why we're
03:04using them. Alone it's not enough. That's why we have to bring in the
03:09technology component. But together you see that amazing results. And when you
03:14think about those results and the power that this potentially has, where do you
03:17see it going? What do you see as being next? You said there are four cancers now
03:21that it can detect. So tell me what those ones are and then where you see this
03:24going as well. Great. Yeah. So right now we're targeting the big four. So we're
03:29talking about breast, lung, colorectal, and prostate. We want to expand into other
03:33cancers. Now if you ask me five years from now, obviously it could be any other
03:37medical condition. Remember, the sense of smell of the dogs, it's very malleable.
03:42So you can train them basically to sniff anything. You mentioned other canine
03:46units, right? We trust them with our lives, right? They sniff drugs, explosives,
03:51missing persons even. So there's no reason why we cannot apply this to other
03:57medical conditions and beyond. And when you think about something like this, it's so
04:01exciting to think about the technology and, you know, what you can do with this.
04:04But also I'm sure a lot of potential patients are a little wary. So how do you
04:08really plan to get this out there to people once it's ready to go, once all the
04:12testing's done? Do you plan to go through doctors and try to have them recommend
04:16it? Do you try to go straight to the consumer? How do you try to get people to
04:19actually use it? Yeah. It's going to be a multi-layered strategy. So we are planning
04:23to sell it online through what we call the physician network. So a physician will have
04:28to review your request and also deliver the results. That's one path that we're
04:33planning to take. Also, we have great partners. So we have health systems that
04:37we're collaborating with and we plan to, so we're doing the clinical studies with
04:41them. We plan to also go to market together with them as well. And when you
04:44think about the future, not just of this company, but kind of what this means for
04:48the whole medical space, how do you feel when you think about that? Is that
04:52exciting? What do you kind of see as next for the entire health and wellness
04:55industry, especially with this product in mind? Sure. So if I can start from cancer, the
05:01fact that there are multiple treatments now, we see the rise of immunotherapy and
05:05gene and cell therapy, that's kind of the secret sauce. Why? Because now there's
05:10something to do about early detection. So I think the more diseases that we'll
05:14see where there are a lot of treatment options, it will make sense to expand and
05:18do early detection for those diseases as well. So it's very exciting.
